Skip to main content
AmigoFish

Theialife’s race to bring a childhood myopia treatment to market

From Beyond Biotech - the podcast from Labiotech · · 44 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

By 2050, nearly half the world's population is expected to be myopic, with around a billion people projected to progress to high myopia — a leading cause of irreversible vision loss later in life. Children face a narrow window in which to intervene, while the eye is still growing, before those structural changes become permanent. Yet despite the scale of the problem, there is still no FDA-approved drug that slows myopia progression in children, a gap underscored just last month when the FDA declined to approve an atropine eye drop for the same use.

My guest today is Thomas Ruggia, President and CEO of Theialife (https://www.theialife.com), a late-stage biotech developing an oral therapy for pediatric myopia derived from a natural caffeine metabolite. Tom joins Theialife after 25 years in ophthalmology leadership, including roles at Johnson & Johnson, Alcon, Novartis, and most recently as CEO of Samsara Vision. We'll talk mechanism, evidence, and the road to Phase 3.

01:49 Meet Thomas Ruggia

06:50 How progressive myopia develops in children and why it's misunderstood

15:55 ND10's mechanism of action

19:51 20 years of Danish compassionate-use data vs. a randomised trial

26:44 Why no FDA-approved pharmacologic therapy exists yet

37:57 Theialife's pipeline beyond myopia

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! (https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&utm_medium=podcast_description&utm_source=podcast)

Stay updated by subscribing to our newsletter (https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&utm_medium=podcast_description&utm_source=podcast)

To dive deeper into the topic:

- Innovation in ophthalmology: How biotechs are reshaping the treatment of eye diseases (https://www.labiotech.eu/in-depth/biotech-ophthalmology-treatment-landscape/)

- Can gene therapy treat vision loss? (https://www.labiotech.eu/in-depth/gene-therapy-treat-vision-loss/)

- Europe’s Ophthalmology Scene Stays Hot for Biotech Funding (https://www.labiotech.eu/trends-news/opthalmology-europe-vc-funding/)

Back to Beyond Biotech - the podcast from Labiotech · Report a problem